Liquidia (LQDA) Set to Release Earnings on Monday

Key Points

• Liquidia is expected to report Q3 2026 results before the market opens on Monday, November 2. Analysts project earnings of $0.922 per share and revenue of $214.18 million, with a conference call scheduled for 8:30 a.m. ET.
• In the prior quarter, Liquidia reported EPS of $0.74, slightly below expectations, but revenue of $171.68 million exceeded estimates and rose 1,842.1% year over year.
• Analyst sentiment is mixed, with an average rating of “Hold” and an average price target of $72.85. The stock recently opened at $42.65, while insiders have sold $25.65 million worth of shares over the past three months.

Liquidia (NASDAQ:LQDA - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of $0.9220 per share and revenue of $214.18 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the company earned ($0.49) earnings per share. The company's quarterly revenue was up 1842.1% on a year-over-year basis. On average, analysts expect Liquidia to post $2.05 EPS for the current fiscal year and $2.13 EPS for the next fiscal year.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $42.65 on Monday. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia has a 52-week low of $22.05 and a 52-week high of $93.61. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of 31.13, a PEG ratio of 0.37 and a beta of 0.61. The business has a 50-day moving average price of $55.83 and a 200-day moving average price of $61.75.

Analyst Upgrades and Downgrades

LQDA has been the topic of several recent analyst reports. Bank of America increased their target price on shares of Liquidia from $79.00 to $92.00 and gave the stock a "neutral" rating in a research note on Thursday, August 13th. Wedbush set a $58.00 price target on Liquidia in a research note on Friday, October 2nd. Royal Bank Of Canada set a $65.00 price target on Liquidia in a report on Thursday, October 15th. Stephens set a $130.00 price target on Liquidia in a report on Friday, July 24th. Finally, Lifesci Capital upgraded Liquidia from a "hold" rating to an "outperform" rating and set a $59.00 price target on the stock in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Liquidia currently has an average rating of "Hold" and an average target price of $72.85.

Insider Activity

In related news, insider Jason Adair sold 73,631 shares of Liquidia stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $69.09, for a total value of $5,087,165.79. Following the completion of the sale, the insider owned 174,606 shares in the company, valued at approximately $12,063,528.54. This trade represents a 29.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Roger Jeffs sold 32,744 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $932,549.12. Following the completion of the sale, the chief executive officer owned 1,125,848 shares of the company's stock, valued at $32,064,151.04. This trade represents a 2.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 564,310 shares of company stock worth $25,648,122 in the last three months. 25.60% of the stock is currently owned by corporate insiders.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.